Loading…
The W.S. Badger Company, Inc. received a warning letter from the FDA's Division of Pharmaceutical Quality Operations I on April 12, 2022, regarding adulteration issues in their finished pharmaceutical products. Based on the subject line, the violations appear to involve current Good Manufacturing Practice (CGMP) non-compliance related to the manufacturing and quality control of finished drugs. While the specific details of the violations are not available from this metadata alone, the warning indicates that the company's pharmaceutical manufacturing operations did not meet FDA's required quality and safety standards.